Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neonatology
  Free Subscription

Articles published in
Eur Respir J
    June 2026
  1. LEIGH MW, Shapiro AJ, Chawla KK, Hazucha MJ, et al
    Tidal breathing nasal nitric oxide measurement as a test for primary ciliary dyskinesia in young children.
    Eur Respir J. 2026;67:2501540.
    >> Share

    May 2026
  2. BORRELLI A, Venturini A, Guidone D, De Santis M, et al
    Rescue of the CFTR chloride channel with nonsense mutations is markedly improved under inflammatory conditions.
    Eur Respir J. 2026;67:2501171.
    >> Share

    April 2026
  3. BORIE R, Mageau A, Guerin C, Weiss M, et al
    Premature hair graying in patients with pulmonary fibrosis and relatives is suggestive of pathogenic variants in telomere related genes.
    Eur Respir J. 2026 Apr 23:2600093. doi: 10.1183/13993003.00093-2026.
    >> Share

    March 2026
  4. GE E, Yu C, Lavigne E, Villeneuve PJ, et al
    Early-life greenness and childhood asthma and allergic rhinitis: An Ontario birth cohort study.
    Eur Respir J. 2026 Mar 12:2502272. doi: 10.1183/13993003.02272-2025.
    >> Share

    February 2026
  5. NUSSSTEIN H, Urbantat RM, Fentker K, Loewe A, et al
    Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor/tezacaftor/ivacaftor therapy.
    Eur Respir J. 2026;67:2500616.
    >> Share

  6. CUINAT S
    SRRM2 and neuroendocrine cell hyperplasia of infancy: connecting neurodevelopment to the lungs.
    Eur Respir J. 2026;67:2501869.
    >> Share

  7. RAPP CK, Rodler J, Mauss-Schwarzer K, Gothe F, et al
    Persistent tachypnoea of infancy (PTI/NEHI) and obesity in SRRM2-related developmental disorder.
    Eur Respir J. 2026;67:2502135.
    >> Share

    January 2026
  8. FATHIMA P, Pan E, Marsh J, Shanthikumar S, et al
    Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort.
    Eur Respir J. 2026;67:2501349.
    >> Share

    December 2025
  9. GRAY DM, Ullah A, Chaya S, Jacobs C, et al
    Lung function trajectories and determinants from birth to 6-years in an African birth cohort: extending trajectories through infancy using oscillometry.
    Eur Respir J. 2025 Dec 5:2500729. doi: 10.1183/13993003.00729-2025.
    >> Share

  10. HALLE O, Graeber SY, Kontsendorn J, Kessemeier C, et al
    Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.
    Eur Respir J. 2025;66:2500150.
    >> Share

  11. EHRHARDT H, Staude B, Abman SH
    Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges.
    Eur Respir J. 2025;66:2501672.
    >> Share

    October 2025
  12. HIRANI D, Selle J, Wagde V, Klymenko O, et al
    Targeting IL6-Edn1-FoxO1 axis enables lung growth in mechanically ventilated newborn mice.
    Eur Respir J. 2025 Oct 9:2401580. doi: 10.1183/13993003.01580-2024.
    >> Share

    September 2025
  13. LOUVRIER C, Soreze Y, Mesinele J, de Becdelievre A, et al
    De novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnea of infancy.
    Eur Respir J. 2025 Sep 18:2500777. doi: 10.1183/13993003.00777-2025.
    >> Share

    August 2025
  14. PLANT BJ, Einarsson GG, Deasy KF, Dahly D, et al
    Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
    Eur Respir J. 2025;66:2402443.
    >> Share

    July 2025
  15. MALL MA, Wainwright CE, Legg J, Chilvers M, et al
    Elexacaftor/tezacaftor/ivacaftor in children aged >/=6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.
    Eur Respir J. 2025;66:2402435.
    >> Share

    June 2025
  16. RATJEN F, Stanojevic S, Gunawardena T, Eckford PDW, et al
    Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.
    Eur Respir J. 2025;65:2401855.
    >> Share

    January 2025
  17. MCEVOY CT, MacDonald KD, Shorey-Kendrick LE, Davies MH, et al
    Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity.
    Eur Respir J. 2025 Jan 16:2400727. doi: 10.1183/13993003.00727-2024.
    >> Share

  18. DIMOPOULOS K, Constantine A
    Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Eur Respir J. 2025;65:2402022.
    >> Share

  19. FOUZAS S, Dimitriou G
    Respiratory oscillometry in neonates and small infants: has the time come?
    Eur Respir J. 2025;65:2402242.
    >> Share

  20. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Eur Respir J. 2025;65:2402127.
    >> Share

  21. WERTHAMMER JW, Gozal D
    The 10-year temporal evolution of respiratory support and associated outcomes in extremely premature infants: betting on a favourable forecast for the next decade.
    Eur Respir J. 2025;65:2402194.
    >> Share

  22. MOISEENKO A, Sinadinos A, Sergijenko A, Pineault K, et al
    Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
    Eur Respir J. 2025;65:2301683.
    >> Share

    November 2024
  23. LOFBERG L, Abrahamsson T, Bjorklund LJ, Hellstrom Westas L, et al
    Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016.
    Eur Respir J. 2024 Nov 7:2401203. doi: 10.1183/13993003.01203-2024.
    >> Share

  24. LIN B, Gong J, Keenan K, Lin F, et al
    Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis.
    Eur Respir J. 2024;64:2400062.
    >> Share

  25. CROMWELL EA, Ostrenga JS, Sanders DB, Morgan W, et al
    Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.
    Eur Respir J. 2024;64:2401146.
    >> Share

    October 2024
  26. WANG G, Hallberg J, Merid SK, Kumar A, et al
    Body mass index trajectories from birth to early adulthood and lung function development.
    Eur Respir J. 2024 Oct 28:2400298. doi: 10.1183/13993003.00298-2024.
    >> Share

  27. URBANTAT RM, Mall MA
    How many functioning ciliated airway epithelial cells are necessary for effective mucociliary clearance?
    Eur Respir J. 2024;64:2401573.
    >> Share

  28. WATERS V, Ratjen F
    Reply to: Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401577.
    >> Share

  29. WATERS V, Quon B, Ratjen F
    Reply to: Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401713.
    >> Share

  30. LIU Y, He KZ, Xu JF
    Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401049.
    >> Share

  31. BEINART D, Forrester DL, Ramakrishnan S
    Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401225.
    >> Share

    September 2024
  32. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    >> Share

  33. REIX P, Chassagnon G
    The younger, the better: lessons learned from real-world studies on CFTR modulators in young children.
    Eur Respir J. 2024;64:2401178.
    >> Share

  34. STAHL M, Dohna M, Graeber SY, Sommerburg O, et al
    Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
    Eur Respir J. 2024;64:2400004.
    >> Share

  35. CHASSAGNON G, Burgel PR
    Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Eur Respir J. 2024;64:2401247.
    >> Share

  36. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    >> Share

    August 2024
  37. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Embracing the challenges of neonatal and paediatric pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401345. doi: 10.1183/13993003.01345-2024.
    >> Share

  38. VARGHESE NP, Austin ED, Galambos C, Mullen MP, et al
    An Interdisciplinary Consensus Approach to Pulmonary Hypertension in Developmental Lung Disorders.
    Eur Respir J. 2024 Aug 15:2400639. doi: 10.1183/13993003.00639-2024.
    >> Share

    July 2024
  39. ZANNIN E, Rigotti C, Schulzke SM, Sindelar R, et al
    Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study.
    Eur Respir J. 2024 Jul 26:2400246. doi: 10.1183/13993003.00246-2024.
    >> Share

  40. AGARWAL S, Jat KR, Gupta S, Sankar J, et al
    Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial.
    Eur Respir J. 2024;64:2400826.
    >> Share

    June 2024
  41. GOSS CH, VanDevanter DR
    Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
    Eur Respir J. 2024;63:2400858.
    >> Share

  42. WATERS V, Shaw M, Perrem L, Quon BS, et al
    A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
    Eur Respir J. 2024;63:2302278.
    >> Share

    May 2024
  43. CAVERLY LJ, Ross BD, Dickson RP
    From gut to lung and back again: early life microbiota in cystic fibrosis.
    Eur Respir J. 2024;63:2400595.
    >> Share

    April 2024
  44. FURSTOVA E, Drevinek P, Novotna S, Libik M, et al
    Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
    Eur Respir J. 2024;63:2400156.
    >> Share

    March 2024
  45. FRAYMAN KB, Macowan M, Caparros-Martin J, Ranganathan SC, et al
    The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis.
    Eur Respir J. 2024 Mar 14:2302290. doi: 10.1183/13993003.02290-2023.
    >> Share

  46. MCKONE EF
    Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap.
    Eur Respir J. 2024;63:2400328.
    >> Share

  47. XU X, Li JD, Green TJ, Wilson L, et al
    Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis.
    Eur Respir J. 2024;63:2301512.
    >> Share

  48. KEREM E, Orenti A, Adamoli A, Hatziagorou E, et al
    Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
    Eur Respir J. 2024;63:2301241.
    >> Share

  49. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    >> Share

  50. CAZIER P, Chassagnon G, Dhote T, Da Silva J, et al
    Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;63:2301794.
    >> Share

    February 2024
  51. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    >> Share

  52. HOUSTON CJ, Alkhatib A, Einarsson GG, Tunney MM, et al
    Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
    Eur Respir J. 2024;63:2301228.
    >> Share

  53. DOONEY M, Saba T
    Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2301392.
    >> Share

  54. BURGEL PR
    Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2400233.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016